Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCU200 for Center-Involved Diabetic Macular Edema
NCT05802329Phase 1Recruiting
- Sponsor
- Ocugen
- Start
- Jan 2024
- Primary completion
- Jul 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of OCU200 in diabetic macular edema (DME) (4 cohorts), sponsored by Ocugen. Primary endpoints: Study Drug-related adverse events at 24 weeks, Treatment-emergent adverse events at 24 weeks and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
OCU200
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05802329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802329.